This two-day conference will serve as a platform to discuss compliance and transparency areas of key concern. Goal is to unravel compliance challenges, define and learn fair market value and develop a consistent, simple and transparent method and strategy for your company.
Tips for the Shipping Process of Pharmaceuticals and Biologics
Find out how to simplify the shipping process for temperature-sensitive pharmaceuticals and biologics and how to contain cost when shipping bulk pharma and biologics.
A new approach to one-way universal shipping has made it far more convenient to send temperature-sensitive healthcare packages. Key changes in package design allow you to forget the pains of bench-time (or sweat time). What’s more, SKU management is simplified with four payload sizes to choose from where each size makes use of the same components and the same pack out is used for both 3-day and 5-day shipments.
Watch this video to see how a few innovative changes in package design can radically improve your temperature-sensitive packaging operations.
In this video podcast, Ben VanderPlas, Global Product Manager at ThermoSafe speaks with Jim Chrzan, Group Publisher of Healthcare Packaging providing insights into the below topics as it relates to ThermoSafe’s latest innovation – LD7 QPMC pallet shipper.
Learn more about the QPMC pallet shipper at thermosafe.com/palletsolutions
Interested in this topic?
Project & Portfolio Management for Pharma and Biotech – EAST
For the upcoming Project and Portfolio Management for Pharma and Biotech Conference, Fleming presents a high-level meeting building on more than a decade of experience in running global Pharma PPM events worldwide.
Patient Adherence and Engagement
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
White Paper: Beyond the Cold Chain
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?